-
1
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Published 2025-01-01Subjects: “…XPO1-ALK…”
Get full text
Article -
2
Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
Published 2025-01-01Subjects: Get full text
Article